Skip to content

[Webinar] Why modernizing hemorrhagic stroke workflows can’t wait
Featuring: Sabareesh Natarajan, MD, MS
Thursday, May 14, 2 PM PT

Register
  • There are no suggestions because the search field is empty.
  • There are no suggestions because the search field is empty.
Press Release

Rapid receives registration approval in Japan

Rapid is now available to hospitals across Japan, helping doctors in that country make smart, fast treatment decisions around stroke.

Share to

Rapid is now available to hospitals across Japan, helping doctors in that country make smart, fast treatment decisions around stroke.

Menlo Park, Calif. — July 8, 2019 – iSchemaView, the worldwide leader in advanced imaging for stroke, has received registration approval under the Japanese Pharmaceutical Affairs Law through third-party review by the Japanese Association for the Advancement of Medical Equipment for its RAPID imaging platform. With this news the technology is available to hospitals across Japan, with the support of Micron, the Japanese RAPID distributor. RAPID is designed to provide physicians with fast, fully automated, and easy-to-interpret imaging that facilitates clinical decision-making around stroke. “Stroke remains the fourth most common cause of death in Japan, and as the population ages, stroke is likely to become an increasing health burden on the country,” said Dr. Manabu Inoue from National Cerebral and Cardiovascular Center. “With RAPID’s AI-powered imaging technology we will be able to better address our patients to provide them with the best routes of care, improving their chances of recovery.” Developed by leading stroke experts, RAPID technology has been selected for use in several ground-breaking trials that have changed treatment guidelines issued by both the American Heart Association and American Stroke Association. The RAPID Artificial Intelligence framework combines deep learning, machine learning and expert feature extraction. Together these provide unparalleled sensitivity and specificity across stroke modules (CT perfusion, MR diffusion and perfusion, CTA and CT ASPECT scoring). Results are then delivered by the RAPID Intelligence Services Platform via PACS, email, text, the RAPID app or corporate partner workflow systems. The Complete RAPID Platform includes: RAPID CTP: fully-automated perfusion maps; accurately quantifies reduced cerebral blood flow, cerebral blood volume and transit time RAPID MRI: fully-automated diffusion and perfusion maps that quantify brain areas with low ADC values, as well as delayed contrast arrival RAPID CTA: automatically delivers CT angiography maps and identifies brain regions with reduced blood vessel density in 2D and 3D outputs RAPID ASPECTS: automatically identifies areas of early ischemic change on non-contrast CT scans, which predicts irreversible injury RAPID Mobile App : Securely review RAPID results from multiple sites with customizable notifications “With approval for RAPID in Japan, we extend a global footprint that gives more hospitals the tools they need to help stroke patients achieve the best outcomes and quality of life,” said Anil Singhal, MD, SVP, Worldwide Operations at iSchemaView. “Our goal is to help as many stroke patients as possible by delivering the only clinically validated, next-generation imaging technology available.” For more information about working with RAPID in Japan, contact Alex Oh, VP International Sales for APAC at +1 (949) 232-3365 or Oh@RAPID.ai . About Micron Micron is a Japanese leading imaging CRO and provides clinical trial support services with expertise in medical image handling. Micron offers a wide range of services, including imaging protocol standardization, image analysis, site management, and clinical monitoring to enhance the efficiency, reproducibility, and reliability of clinical trials. The company also engages in the development, sales, and marketing of the imaging analysis software which can be utilized in clinical trials for evaluating the efficacy or safety of drugs and in clinical disease progression. RAPID is one of such software, and was approved as a medical device by Pharmaceutical Affairs Law successfully in a short period of time with the great contribution of Micron. For more information, visit www.micron-kobe.com

Contact PR

Jessica Stebing

Jessica Stebing

Group Manager, Marketing Communications

stebing@rapidai.com

Get to know Rapid in the real world

View All Resources
Video - Lumina Webinar Replay

Webinar

The end of manual head & neck reconstructions // A faster path with Lumina 3D

In this webinar, we focus on the challenges and opportunities in 3D head and neck CTA reconstruction workflows. Our speakers share real-world insights on how the Lumina 3D platform can have a tangible impact on CT workflow, scanner throughput, and diagnosis.
Radiology Rewired Podcast - Episode 1 Thumbnail

Podcast

AI Meets Imaging | Radiology Rewired | Ep. 1

In the debut episode of Radiology Rewired, RapidAI’s new clinician-led podcast hosted by Dr. Singh, Dr. Greg Albers—founder of RapidAI and professor of neurology at Stanford University—shares the story behind one of medicine’s most important breakthroughs: extending the stroke treatment window to 24 hours. Dr. Albers recounts how decades of imaging research led from early diffusion-perfusion MRI to automated AI tools that changed global stroke guidelines and transformed how teams diagnose and treat patients. This episode explores how deep clinical AI is reshaping radiology and why credible, clinician-led innovation remains essential for the next generation of healthcare technology.
Resources - multistakeholder white paper

White paper

The clinical AI champion's guide: getting to "yes" in complex health systems

This guide is designed for internal champions, clinicians, service line leaders, and administrators who believe in the potential of AI to improve care and operations. It offers practical insights from a C-suite advisory panel from leading health systems across the nation on how decisions are made, who typically drives them forward, and what tools and strategies are proving most effective in securing alignment and buy-in across the system.